STOCKS
Chris Quigley
Contributing Editor,
The Prudent Speculator
Follow
About Chris
As a member of the research team Chris Quigley conducts fundamental research and analysis. He is responsible for generating new investment ideas and maintains company, industry and macroeconomic models. Additionally, he is a regular contributor to the firms market commentary and newsletter. Chris earned his B.A. degree in Economics from the University of Southern California in 2011. During the summers of 2009 and 2010, Chris interned at AFAM Capital where he worked with both the research and portfolio management teams. Chris joined the team in August of 2011. He is currently a Level II candidate in the CFA Program.
Chris's Articles
Shares of Walt Disney (DIS) plunged after the company reported weaker-than-expected Disney+ subscriber growth in fiscal Q4, reports Chris Quigley, value investor and contributing editor to The Prudent Speculator.
Chris Quigley
CONSUMER
Medtronic PLC (MDT) released fiscal Q1 financial results that beat analyst estimates on both top and bottom lines, suggests value investing specialist Chris Quigley, contributing editor to The Prudent Speculator.
Chris Quigley
HEALTHCARE
Tickers: MDT
Shares of Biogen (BIIB) fell after a West Virginia District Court ruled against the firm in a patent suit brought by Mylan Inc. (MYL) related to its blockbuster multiple sclerosis drug Tecfidera, notes Chris Quigley, a value investing specialist and contributing editor to The Prudent Speculator.
Chris Quigley
HEALTHCARE
We retain our enthusiasm for the long-term prospects of equities in general, and our broadly diversified portfolios of what we believe to be undervalued stocks in particular, notes Chris Quigley, contributing editor to The Prudent Speculator.
Chris Quigley
FINANCIALS